The END Fund

What problem is The END Fund’s working on?

The END Fund reports that 1.7 billion people worldwide need treatment for intestinal worms, most of them children. Neglected tropical diseases (NTDs) cause severe pain and long-term disability and lead to death for more than 170,000 people per year. Children who are infected suffer from malnutrition, cognitive impairment, stunted growth, and the inability to attend school. Many people who are infected are unable to work to provide for themselves or their families and are left in a cycle of poverty.

What does The END Fund do?

The END Fund mobilises resources from a diverse range of investors and directs them to partners who can deliver them where they will have the most impact. It focuses on delivering NTD treatments by:

• Growing and engaging a community of activist-philanthropists.
• Managing high-impact strategic investments.
• Working in collaboration with government, NGO, pharmaceutical, and academic partners.
• Taking a systems approach to understanding, engaging with, and influencing the broad ecosystem of stakeholders working on ending NTDs.

More specifically, The END Fund:

• Raises and directs money for NTD elimination through outreach; awareness-building; and engagement with donors, philanthropists, and leaders within the private and public sectors.
• Strategically manages an investment portfolio with the aim of ending widespread NTDs by 2030, identifying key investment opportunities and helping build coalitions and collaborations.
• Works with NGOs to design and implement NTD programmes.
• Provides technical and strategic support to partner organisations, institutions, industry, and governments; and manages grants.
• Conducts monitoring and evaluation to understand the impact of its various initiatives, and help advance the knowledge base of the NTD and global health communities, thus informing programmes and decisions.

The END Fund’s deworming branch helps treat and work toward the elimination of schistosomiasis and soil-transmitted helminthiasis.

As of 2022, The END Fund reports that its work has helped provide over 1.2 billion treatments since its founding in 2012, with 118 million treatments in 2021 alone.

What evidence is there of The END Fund’s effectiveness?

The END Fund’s deworming programme meets our criteria to be listed on our platform because it was previously one of our recommended charities due to GiveWell’s inclusion of it as a top-rated giving opportunity from 2016 to 2022. GiveWell’s decision to no longer recommend The END Fund was not based on any shift in thinking about The END Fund, but rather a change in its top charity criteria. (See more about GiveWell’s decision and how that decision affects our recommended charities.)

Some research shows that deworming has positive effects on improved life outcomes like school attendance and income earnings. There is also some uncertainty surrounding findings that link deworming programs to improved life outcomes — see GiveWell’s in-depth report on the case for mass deworming.

We intend to reevaluate the status of all of the charities listed on our platform that are working on deworming programmes after one of our trusted evaluators, Founders Pledge, publishes its review of deworming’s cost-effectiveness. (Our trusted evaluators are charitable giving experts who focus on impact — their research into the best charities means your donations can do even more good. Learn more about charity evaluators we trust and why.)

Why donate through the Giving What We Can donation platform?

Your donations through our portal are tax deductible in the UK, US, and the Netherlands. Giving What We Can does not take any fees from donors using our platform or from charities listed on our platform. We are independently funded to promote our mission of making giving effectively and significantly a cultural norm. Read more on our transparency page.